The translocator protein as a drug target in Alzheimer's disease

Sook W. Chua, Michael Kassiou, Lars M. Ittner*

*Corresponding author for this work

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The translocator protein (TSPO) recently emerged as a potential drug target in Alzheimer's disease (AD). This has been fuelled mainly by positron emission topography studies that show the upregulation of TSPO in AD, especially in relation to microgliosis and astrogliosis in amyloid-β and tau pathology. Although data as to the exact role of TSPO in AD is still inconclusive, TSPO appears to be involved in neuroinflammatory processes and AD has been shown to involve substantial inflammation. Therefore, further development and investigation of the pharmacological effect of TSPO ligands in AD pathology are warranted.

Original languageEnglish
Pages (from-to)439-448
Number of pages10
JournalExpert Review of Neurotherapeutics
Volume14
Issue number4
DOIs
Publication statusPublished - Apr 2014
Externally publishedYes

Keywords

  • Alzheimer's disease
  • Drug development
  • Microglia
  • Neuroinflammation
  • Positron emission topography
  • Translocator protein
  • TSPO

Fingerprint Dive into the research topics of 'The translocator protein as a drug target in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this